Benzinga | Nov 3, 2021 05:18PM EDT

Heron Therapeutics Q3 EPS $(0.51) Beats $(0.61) Estimate, Sales $23.23M Miss $25.51M Estimate

Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.61) by 16.39 percent. This is a 20.31 percent increase over losses of $(0.64) per share from the same period last year. The company reported quarterly sales of $23.23 million which missed the analyst consensus estimate of $25.51 million by 8.94 percent. This is a 16.35 percent increase over sales of $19.96 million the same period last year.